Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-24 Mln
-
ROE
-47 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
43,593,100
7 Years Aggregate
CFO
$-288.49 Mln
EBITDA
$-266.78 Mln
Net Profit
$-314.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Baudax Bio (BXRX)
| -54.5 | -18.0 | -58.7 | -98.7 | -98.2 | -- | -- |
|
BSE Sensex*
| -11.7 | -2.7 | -8.0 | -8.0 | 6.2 | 7.8 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2021
|
2020
|
|---|---|---|---|
|
Baudax Bio (BXRX)
| -99.3 | -78.3 | -85.4 |
|
S&P Small-Cap 600
| 13.9 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Baudax Bio (BXRX)
|
0.0 | 1.0 | 0.3 | -7.2 | -4,974.2 | -- | -- | 0.7 |
| 8.3 | 36.9 | 0.0 | -4.4 | -- | 1617.9 | -- | 201.6 |
Shareholding Pattern
View DetailsAbout Baudax Bio (BXRX)
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in... combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania. Read more
-
President, CEO & Director
Dr. Geraldine A. Henwood Ph.D.
-
President, CEO & Director
Dr. Geraldine A. Henwood Ph.D.
-
Headquarters
Malvern, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Baudax Bio (BXRX)
What is the current share price of Baudax Bio Inc (BXRX) Today?
The share price of Baudax Bio Inc (BXRX) is $0.01 (NASDAQ) as of 02-May-2024 09:30 EDT. Baudax Bio Inc (BXRX) has given a return of -98.15% in the last 3 years.
What is the current PB & PE ratio of Baudax Bio Inc (BXRX)?
Since, TTM earnings of Baudax Bio Inc (BXRX) is negative, P/E ratio is not available.
The P/B ratio of Baudax Bio Inc (BXRX) is 0.68 times as on 02-May-2024, a 84 discount to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Baudax Bio Inc (BXRX)?
The 52-week high and low of Baudax Bio Inc (BXRX) are Rs -- and Rs -- as of 31-May-2026.
What is the market cap of Baudax Bio Inc (BXRX)?
Baudax Bio Inc (BXRX) has a market capitalisation of $ 1 Mln as on 02-May-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Baudax Bio Inc (BXRX)?
Before investing in Baudax Bio Inc (BXRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.